Leading the Way in Life Science Technologies

GEN Exclusives

More »
Genetics - Related Content
  • Insight & Intelligence™
  • More »
  • PREDICTING THE RISK FOR HYPERTENSION
    Interview with TanYa Gwathmey, Ph.D., Post-doctoral Research Associate, Hypertension and Vascular Research Center, Hypertension Core Laboratory, Wake Forest University School of Medicine
  • GENETIC LINK FOUND BETWEEN REPTILE AND HUMAN HEART EVOLUTION
    - Interview with Benoit Bruneau, Ph.D., Associate Investigator, Gladstone Institute of Cardiovascular Disease, and Associate Professor of Pediatrics, University of California-San Francisco
  • GENE EVOLUTION PROCESS DISCOVERED
    - Interview with Ian Wood, Ph.D., Senior Lecturer, Institute of Membrane and Systems Biology, Faculty of Biological Sciences, University of Leeds
  • NEW GENETIC CLUES TO BLOOD PRESSURE REGULATION
    - Interview with Daniel Levy, M.D., Director of the National Heart, Lung, and Blood Institute's Framingham Heart Study and Professor of Medicine at the Boston University School of Medicine
  • MICROSIZING GENETICS TESTING
    - Interview with James Landers, Ph.D., Professor of Chemistry, Professor of Mechanical Engineering, and Associate Professor of Pathology, University of Virginia

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »